EMERALD: Updated Phase 3 Results by Duration of Prior CDK4/6i Treatment
EMERALD phase 3 trial of elacestrant versus standard of care endocrine therapy in patients with ER+/HER2- metastatic breast cancer: updated results by duration of prior CDK4/6i in metastatic setting. SABCS 2022. Oral Presentation
Tagraxofusp: Phase 1 Study (+/- chemotherapy) in Pediatric Patients with R/R CD123 expressing Heme Malignancies
Phase I Study of Tagraxofusp +/- Chemotherapy in Pediatric Patients with R/R CD123-Expressing Hematologic Malignancies: A TACL Consortium Trial. ASH 2022. Poster
Tagraxofusp: Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial
Patients with BPDCN and Prior/Concomitant Hem Malignancies: Subgroup Analysis of Pivotal Trial. ASH 2022. Poster
Tagraxofusp: Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP
Preliminary Results from an Observational Study of Patients with BPDCN Treated in the European EAP. ASH 2022. Poster
ELEVATE: A Phase 1b/2 Umbrella Study Evaluating Elacestrant in Various Combinations
ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating elacestrant in Various Combinations in Women and Men with Metastatic Breast Cancer (mBC). SABCS 2022. Poster
EMERALD: Phase 3 Subgroup Analysis
Elacestrant Versus Fulvestrant or Aromatase Inhibitor in a Phase 3 Trial Evaluating Elacestrant, an Oral Selective Estrogen Receptor Degrader Versus Standard of Care Endocrine Monotherapy for ER+/HER2- Advanced/Metastatic Breast Cancer: Subgroup Analysis from EMERALD. ESMO 2022. Poster
EMERALD: Subgroup Analysis of patients with no prior chemotherapy
EMERALD: Subgroup analysis of patients with no prior chemotherapy in a phase 3 trial evaluating elacestrant versus investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC). ASCO 2022. Poster
Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF
Tagraxofusp: Phase 1/2 Study of Tagraxofusp in Patients with Relapsed/Refractory MF. ASH 2021. Oral Presentation
Tagraxofusp in Patients with Chronic Myelomonocytic Leukemia (CMML): Updated Results of an Ongoing Phase 1/2 Trial
TAG in Patients with CMML: Updated Results from Phase 1/2 Trial. ASH 2021. Oral Presentation
Tagraxofusp: Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease
Tagraxofusp Subanalysis of Pivotal Trial in BPDCN by Age and Baseline Disease. ASH 2021. Oral Presentation